^
Association details:
| Biomarker: | EPHA2 expression + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | BCY6033 (Microtubule inhibitor, EphA2 receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
333 / 8 - Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small lung cancer (NSCLC) patient derived xenografts
Published date:
03/09/2022
Excerpt:
The activity of BCY6033 was evaluated in EphA2 expressing EGFR mutant PDX models, DFCI-161 and DFCI-220 in NSG mice….BCY6033 treatment led to significant tumor growth inhibition with >80% tumor regressions in both DFCI-161 and DFCI-220 PDX models. Re-challenge of tumor out-growth showed that they retain sensitivity to BCY6033 treatment.
